CN105823877B - 卵巢癌的生物标记：ctap3-相关蛋白质 - Google Patents

卵巢癌的生物标记：ctap3-相关蛋白质 Download PDF

Info

Publication number
CN105823877B
CN105823877B CN201510890662.5A CN201510890662A CN105823877B CN 105823877 B CN105823877 B CN 105823877B CN 201510890662 A CN201510890662 A CN 201510890662A CN 105823877 B CN105823877 B CN 105823877B
Authority
CN
China
Prior art keywords
biomarker
biomarkers
ovarian cancer
capture agent
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510890662.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105823877A (zh
Inventor
Z·张
D·W·尚
E·T·冯
Z·王
F·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Espira Women's Health Co
Johns Hopkins University
Original Assignee
Espira Women's Health Co
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Espira Women's Health Co, Johns Hopkins University filed Critical Espira Women's Health Co
Publication of CN105823877A publication Critical patent/CN105823877A/zh
Application granted granted Critical
Publication of CN105823877B publication Critical patent/CN105823877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201510890662.5A 2005-06-22 2006-06-21 卵巢癌的生物标记：ctap3-相关蛋白质 Active CN105823877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69332405P 2005-06-22 2005-06-22
US60/693,324 2005-06-22
CN200680029695.XA CN101243319B (zh) 2005-06-22 2006-06-21 卵巢癌的生物标记：ctap3-相关蛋白质

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200680029695.XA Division CN101243319B (zh) 2005-06-22 2006-06-21 卵巢癌的生物标记：ctap3-相关蛋白质

Publications (2)

Publication Number Publication Date
CN105823877A CN105823877A (zh) 2016-08-03
CN105823877B true CN105823877B (zh) 2022-02-25

Family

ID=37595819

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510890662.5A Active CN105823877B (zh) 2005-06-22 2006-06-21 卵巢癌的生物标记：ctap3-相关蛋白质
CN200680029695.XA Active CN101243319B (zh) 2005-06-22 2006-06-21 卵巢癌的生物标记：ctap3-相关蛋白质

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200680029695.XA Active CN101243319B (zh) 2005-06-22 2006-06-21 卵巢癌的生物标记：ctap3-相关蛋白质

Country Status (10)

Country Link
US (5) US20070172902A1 (https=)
EP (1) EP1907841B1 (https=)
JP (1) JP5159619B2 (https=)
CN (2) CN105823877B (https=)
AT (1) ATE438856T1 (https=)
AU (1) AU2006262182B2 (https=)
CA (1) CA2611340A1 (https=)
DE (1) DE602006008310D1 (https=)
IL (3) IL187867A (https=)
WO (1) WO2007002264A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
EP1877795A4 (en) * 2005-05-02 2010-04-28 Brigham & Womens Hospital DIAGNOSTIC PROFILE MANUFACTURE OF SERUM ANTIBODIES
CN101473041B (zh) * 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
JP5238171B2 (ja) * 2007-03-14 2013-07-17 株式会社東芝 光導波路型抗体チップ
US8221984B2 (en) 2007-03-27 2012-07-17 Vermillion, Inc. Biomarkers for ovarian cancer
KR100997463B1 (ko) 2007-04-30 2010-11-30 (주)예비티 난소암 진단용 조성물, 그 키트 및 진단 방법
US8664358B2 (en) * 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
WO2009058331A2 (en) * 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
CA2718251A1 (en) 2008-03-10 2009-09-17 Lineagen, Inc. Copd biomarker signatures
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
US20120004854A1 (en) * 2008-05-28 2012-01-05 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
JP5422785B2 (ja) * 2008-09-12 2014-02-19 国立大学法人名古屋大学 質量分析法を利用した複数癌腫の血液検出のための方法および生物マーカー
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
JP6076901B2 (ja) * 2010-07-16 2017-02-15 スティヒティング フェーユーエムセー 被験者の血液サンプル中の疾患マーカーの存在の分析方法
CN102375063A (zh) * 2010-08-23 2012-03-14 湖州赛尔迪生物医药科技有限公司 一种常见蛋白质的免疫质谱试剂盒及制备方法
JP5686431B2 (ja) * 2011-01-28 2015-03-18 学校法人 京都産業大学 卵巣癌の検出方法、並びに、キット
US20140024552A1 (en) * 2011-02-15 2014-01-23 The Johns Hopkins University Compositions and methods for diagnosing ovarian cancer
CA2830461C (en) * 2011-03-18 2021-06-29 Thomas Wurdinger A method of analysing a blood sample of a subject for the presence of a disease marker
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc
US20130196350A1 (en) * 2012-01-31 2013-08-01 Bio-Rad Laboratories, Inc. Sensitivity and specificity for ovarian cancer
WO2014144627A1 (en) 2013-03-15 2014-09-18 Abbott Laboratories Automated diagnostic analyzers having rear accessible track systems and related methods
JP6351703B2 (ja) 2013-03-15 2018-07-04 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 垂直配置カルーセルを有する自動診断分析装置および関連方法
CA2914918C (en) * 2013-05-10 2023-10-10 Johns Hopkins University Compositions and methods for ovarian cancer assessment having improved specificity
US20150126384A1 (en) * 2013-11-06 2015-05-07 Vermillion, Inc. Prognostic Biomarkers in Patients with Ovarian Cancer
CN105821030A (zh) * 2015-01-04 2016-08-03 彭霞 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
WO2020218465A1 (ja) * 2019-04-26 2020-10-29 中外製薬株式会社 子宮内膜症の診断方法、病態モニタリング方法及びキット
JP7443815B2 (ja) * 2020-02-25 2024-03-06 東ソー株式会社 統計的手法によるクロマトグラムの分類方法
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
WO2025237351A1 (zh) * 2024-05-16 2025-11-20 上海施江生物科技有限公司 一种磷类化合物在抗肿瘤方面中的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192738A4 (en) 1984-08-29 1987-06-25 Chiron Corp EXPRESSION OF HUMAN CONJUNCTIVE TISSUE ACTIVATOR AND RELATED PEPTIDES.
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US5366866A (en) 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
AU3332193A (en) * 1991-12-30 1993-07-28 Georgetown University Measurement of mdgf1 and its receptor as prognostic variables in breast cancer
EP0677106A4 (en) * 1993-01-07 1998-12-09 Univ South Florida GROWTH FACTORS MADE OF LEUKOCYTEN.
EP0708838A1 (en) * 1993-07-29 1996-05-01 PHARMACIA & UPJOHN COMPANY Use of heparanase to identify and isolate anti-heparanase compound
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
US6491906B1 (en) * 1995-06-01 2002-12-10 The Regents Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
EP1145541B1 (en) * 1998-11-24 2012-11-21 Niksun, Inc. Apparatus and method for collecting and analyzing communications data
US6683881B1 (en) * 1999-05-28 2004-01-27 Ericsson Inc. Interface between an SS7 gateway and an IP network
US7058973B1 (en) * 2000-03-03 2006-06-06 Symantec Corporation Network address translation gateway for local area networks using local IP addresses and non-translatable port addresses
US7111076B2 (en) * 2000-04-13 2006-09-19 Intel Corporation System using transform template and XML document type definition for transforming message and its reply
US20020107951A1 (en) * 2000-09-11 2002-08-08 William Teague Report group management
US20020114274A1 (en) * 2000-09-19 2002-08-22 Sturges James H. Packet based network for supporting real time applications
US20030026268A1 (en) * 2000-11-28 2003-02-06 Siemens Technology-To-Business Center, Llc Characteristic routing
US7882555B2 (en) * 2001-03-16 2011-02-01 Kavado, Inc. Application layer security method and system
US20050107586A1 (en) * 2001-07-31 2005-05-19 Su Eric W. Lp354 Mammalian secreted protein
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US7146403B2 (en) * 2001-11-02 2006-12-05 Juniper Networks, Inc. Dual authentication of a requestor using a mail server and an authentication server
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7428597B2 (en) * 2002-03-28 2008-09-23 Sap Ag Content-based routing system and method
US7206862B2 (en) * 2002-04-24 2007-04-17 Microsoft Corporation Method and apparatus for efficiently matching responses to requests previously passed by a network node
NZ562192A (en) * 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US7280559B2 (en) * 2002-08-16 2007-10-09 Mitsubishi Electric Research Laboratories, Inc. Distributed application layer protocol converter for communications network
US7321556B1 (en) * 2002-10-28 2008-01-22 Ipolicy Networks, Inc Application prioritization policy engine
US20040128360A1 (en) * 2002-12-31 2004-07-01 Robert Petri Channel server
US7895589B2 (en) * 2003-02-26 2011-02-22 International Business Machines Corporation Dynamic data-driven application integration adapters
US6898632B2 (en) * 2003-03-31 2005-05-24 Finisar Corporation Network security tap for use with intrusion detection system
US8027922B2 (en) * 2003-07-14 2011-09-27 Sprint Communications Company L.P. Integration infrastructure
JP2005057435A (ja) * 2003-08-01 2005-03-03 Sony Corp クライアント機器及びクライアント機器におけるコンテンツ処理方法、並びにコンテンツ提供システム
JP2007504463A (ja) * 2003-09-05 2007-03-01 ロイヤル ウィメンズ ホスピタル 卵巣癌用の診断マーカー
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
AU2005236075A1 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20050289538A1 (en) * 2004-06-23 2005-12-29 International Business Machines Corporation Deploying an application software on a virtual deployment target
EP1766408A2 (en) * 2004-07-09 2007-03-28 Tripath Imaging, Inc. Methods and compositions for the detection of ovarian cancer
EP2848942B1 (en) * 2004-07-14 2017-03-08 The Regents of The University of California Biomarkers for early detection of ovarian cancer
MX2007001357A (es) * 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
AU2006223374B2 (en) * 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
US7483429B2 (en) * 2005-05-18 2009-01-27 International Business Machines Corporation Method and system for flexible network processor scheduler and data flow

Also Published As

Publication number Publication date
EP1907841B1 (en) 2009-08-05
US11255857B2 (en) 2022-02-22
ATE438856T1 (de) 2009-08-15
US20220317126A1 (en) 2022-10-06
EP1907841A2 (en) 2008-04-09
DE602006008310D1 (de) 2009-09-17
IL187867A (en) 2013-12-31
IL251791B (en) 2020-10-29
CN105823877A (zh) 2016-08-03
IL229974A0 (en) 2014-01-30
AU2006262182B2 (en) 2012-04-05
WO2007002264A2 (en) 2007-01-04
US9816995B2 (en) 2017-11-14
JP2008547025A (ja) 2008-12-25
JP5159619B2 (ja) 2013-03-06
AU2006262182A1 (en) 2007-01-04
IL229974A (en) 2017-04-30
CA2611340A1 (en) 2007-01-04
CN101243319B (zh) 2016-01-06
US20070172902A1 (en) 2007-07-26
CN101243319A (zh) 2008-08-13
US20140274787A1 (en) 2014-09-18
WO2007002264A3 (en) 2007-08-16
IL187867A0 (en) 2008-03-20
IL251791A0 (en) 2017-06-29
US20100075342A1 (en) 2010-03-25
US20180196054A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
CN105823877B (zh) 卵巢癌的生物标记：ctap3-相关蛋白质
US20210181207A1 (en) Biomarkers for Ovarian Cancer: B2 Microglobulin
JP6010597B2 (ja) 卵巣癌用のバイオマーカー
US8221984B2 (en) Biomarkers for ovarian cancer
CN101268367A (zh) 卵巢癌的生物标记
AU2015210343B2 (en) BIOMARKERS FOR OVARIAN CANCER: ß-2 MICROGLOBULIN
AU2012216473B2 (en) Biomarkers for ovarian cancer: beta-2 microglobulin
US20150153348A1 (en) BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN
MX2008000090A (en) Biomarker for ovarian cancer:ctap3-related proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American Maryland

Applicant after: THE JOHNS HOPKINS University

Applicant after: Espira women's health company

Address before: American Maryland

Applicant before: THE JOHNS HOPKINS University

Applicant before: VERMILLION, Inc.

GR01 Patent grant
GR01 Patent grant